Type 2 diabetes remission: why follow-up still matters
Type 2 diabetes remission is possible for some adults. We examine the trials, relapse, medication safety, and why ongoing clinical follow-up matters.
Read the articleExplore the journal
Type 2 diabetes remission is possible for some adults. We examine the trials, relapse, medication safety, and why ongoing clinical follow-up matters.
Read the articleAlternate-day fasting offers a modest weight-loss advantage in some trials. We examine the evidence, long-term limits, and who faces greater medical risk.
Read the articleFasting headaches are not proof of metabolic benefit. Learn how caffeine, medicines, migraine and warning signs should shape your next step.
Read the articleFasting windows can help glucose control and weight in some adults, but timing is secondary. Safety, adherence and medical supervision decide if it works.
Read the articleFasting can improve some markers, but glucose-lowering medicine can alter risk. If you use insulin or SGLT2 drugs, get medical guidance before changing timing.
Read the articleTime-restricted eating can improve some weight and glucose markers, but medication risks, adherence, and long-term outcomes are still uncertain.
Read the articleA new trial suggests an 8–10-hour eating window can modestly improve metabolic risk markers, but it is a routine—not a replacement for care.
Read the articleLiver fat is closely tied to insulin resistance, but it is a metabolic risk signal, not a verdict. The useful next step is fibrosis risk, not panic.
Read the articleGlycaemic variability can reveal glucose swings that HbA1c hides, but the evidence supports using it as a clinical clue, not a stand-alone diagnosis.
Read the articleOMAD can reduce eating opportunities, but evidence points to calorie reduction and adherence, not proven longevity gains, as the main explanation for adults.
Read the articleFind a little clarity